Exploring Appropriate Reference Intervals and Clinical Decision Limits for Glucose-6-Phosphate Dehydrogenase Activity in Individuals From Guangzhou, China
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Quantitative detection of glucose-6-phosphate dehydrogenase (G6PD) is commonly done to screen for G6PD deficiency. However, current reference intervals (RIs) of G6PD are unsuitable for evaluating G6PD-activity levels with local populations or associating G6PD variants with hemolysis risk to aid clinical decision-making. We explored appropriate RIs and clinical decision limits (CDLs) for G6PD activity in individuals from Guangzhou, China. Methods: We enrolled 5,852 unrelated individuals between 2020 and 2022 and screened their samples in quantitative assays for G6PD activity. We conducted further investigations, including G6PD genotyping, thalassemia genotyping, follow-up analysis, and statistical analysis, for different groups. Results: In Guangzhou, the RIs for the G6PD activities were 11.20–20.04 U/g Hb in male and 12.29–23.16 U/g Hb in female. The adjusted male median and normal male median (NMM) values were 15.47 U/g Hb and 15.51 U/g Hb, respectively. A threshold of 45% of the NMM could be used as a CDL to estimate the probability of G6PD variants. Our results revealed high hemolysis-risk CDLs (male: <10% of the NMM, female: <30% of the NMM), medium hemolysis-risk CDLs (male: 10%–45% of the NMM, female: 30%–79% of the NMM), and low hemolysis-risk CDLs (male: ≥ 45% of the NMM, female: ≥ 79% of the NMM). Conclusions: Collectively, our findings contribute to a more accurate evaluation of G6PDactivity levels within the local population and provide valuable insights for clinical decisionmaking. Specifically, identifying threshold values for G6PD variants and hemolysis risk enables improved prediction and management of G6PD deficiency, ultimately enhancing patient care and treatment outcomes.
Abstract
Background: Quantitative detection of glucose-6-phosphate dehydrogenase (G6PD) is commonly done to screen for G6PD deficiency. However, current reference intervals (RIs) of G6PD are unsuitable for evaluating G6PD-activity levels with local populations or associating G6PD variants with hemolysis risk to aid clinical decision-making. We explored appropriate RIs and clinical decision limits (CDLs) for G6PD activity in individuals from Guangzhou, China. Methods: We enrolled 5,852 unrelated individuals between 2020 and 2022 and screened their samples in quantitative assays for G6PD activity. We conducted further investigations, including G6PD genotyping, thalassemia genotyping, follow-up analysis, and statistical analysis, for different groups. Results: In Guangzhou, the RIs for the G6PD activities were 11.20–20.04 U/g Hb in male and 12.29–23.16 U/g Hb in female. The adjusted male median and normal male median (NMM) values were 15.47 U/g Hb and 15.51 U/g Hb, respectively. A threshold of 45% of the NMM could be used as a CDL to estimate the probability of G6PD variants. Our results revealed high hemolysis-risk CDLs (male: <10% of the NMM, female: <30% of the NMM), medium hemolysis-risk CDLs (male: 10%–45% of the NMM, female: 30%–79% of the NMM), and low hemolysis-risk CDLs (male: ≥ 45% of the NMM, female: ≥ 79% of the NMM). Conclusions: Collectively, our findings contribute to a more accurate evaluation of G6PDactivity levels within the local population and provide valuable insights for clinical decisionmaking. Specifically, identifying threshold values for G6PD variants and hemolysis risk enables improved prediction and management of G6PD deficiency, ultimately enhancing patient care and treatment outcomes.
참고문헌 (25)
- Ozarda Y, "Distinguishing reference intervals and clinical decision limits – a review by the IFCC Committee on Reference Intervals and Decision Limits", Crit Rev Clin Lab Sci, 55, pp.420~431 (2018)
- CLSI, "Defining, establishing, and verifying reference intervals in the clinical laboratory; Approved Guideline" (2010), Clinical and Laboratory Standards Institute
- Coşkun A, "Personalized reference intervals in laboratory medicine : a new model based on within-subject biological variation", Clin Chem, 67, pp.374~384 (2021)
- Luzzatto L, "Glucose-6-phosphate dehydrogenase deficiency", Blood, 136, pp.1225~1240 (2020)
- "Technical consultation to review the classification of glucose-6-phosphate dehydrogenase (G6PD)" (2023)[URL]
- Domingo GJ, "G6PD testing in support of treatment and elimination of malaria : recommendations for evaluation of G6PD tests", Malar J, 12, pp.391~ (2013)
- "Guide to G6PD deficiency rapid diagnostic testing to support P. vivax radical cure, 2018" (2018)[URL]
- Chen Q, "Target-allele-specific probe single-base extension(TASP-SBE) : a novel MALDI–TOF–MS strategy for multi-variants analysis and its application in simultaneous detection of α-", β-thalassemia mutations, 2023, pp.142, 445~456
- Roper D, "Laboratory diagnosis of G6PD deficiency. A British Society for Haematology guideline", Br J Haematol, 189, pp.24~38 (2020)
- "Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale" (2016)[URL]
- He Y, "Glucose-6-phosphate dehydrogenase deficiency in the Han Chinese population : molecular characterization and genotype-phenotype association throughout an activity distribution", Sci Rep, 10, pp.17106~ (2020)
- Oo NN, "Validation of G6PD point-of-care tests among healthy volunteers in Yangon, Myanmar", PLoS One, 11, pp.e0152304~ (2016)
- Lai K, "The prevalence of thalassemia in mainland China : evidence from epidemiological surveys", Sci Rep, 7, pp.920~ (2017)
- Ye W, "Correlation analysis of G6PD activity level and thalassemia", China Pract Med, 15, pp.95~97 (2020)
- Huang S, "Relationship between G6PD activity and thalassemia", Chin J Gen Pract, 10, pp.1140~1141 (2012)
- Tang L, "Correlation analysis between carrying different thalassemia genes and G6PD activity", J Chin Prescrip Drug, 19, pp.159~160 (2021)
- Pfeffer DA, "Correction : quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry : a systematic review and meta-analysis", PLoS Med, 17, pp.e1003311~ (2020)
- Domingo GJ, "Addressing the gender-knowledge gap in glucose-6-phosphate dehydrogenase deficiency : challenges and opportunities", Int Health, 11, pp.7~14 (2019)
- "How to use a G6PD rapid diagnostic test (for detecting glucose-6-phosphate dehydrogenase deficiency): a guide for training at health facility level" (2018)[URL]
- Oliveira RAG, "A novel point mutation in a class IV glucose-6-phosphate dehydrogenase variant (G6PD Sao Paulo) and polymorphic G6PD variants in Sao Paulo State, Brazil", Genet Mol Biol, 32, pp.251~254 (2009)
- Lee J, "Genetic profiles of Korean patients with glucose-6-phosphate dehydrogenase deficiency", Ann Lab Med, 37, pp.108~116 (2017)
- Liu Z, "Chinese newborn screening for the incidence of G6PD deficiency and variant of G6PD gene from 2013 to 2017", Hum Mutat, 41, pp.212~221 (2020)
- Lacerda MVG, "Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria", N Engl J Med, 380, pp.215~228 (2019)
- Commons RJ, "Tafenoquine for the radical cure and prevention of malaria : the importance of testing for G6PD deficiency", Med J Aust, 212, pp.152~153 (2020)
- Li Z, "Genotypic and phenotypic characterization of glucose-6-phosphate dehydrogenase (G6PD) deficiency in Guangzhou, China", Hum Genomics, 17, pp.26~ (2023)